Generics market failings cost Mexico $144 million annually, says report

At two years after the entry of the first copycat product, the penetration of generic drugs reaches 21.4% of the market in Mexico, where in the USA it climbs to 89% and in Canada it is 74%.

That is one of a series of findings from a report that show just how bad the market is for drugs with expired patents in Mexico, and how it is failing the country’s people.

"In Mexico, it takes, on average, more than two years between the expiration of a patent and the launch of the first generic, while in the USA, the generic is introduced almost immediately"